1,721,065 research outputs found
lj20t00S107p
No full textI m m u n o p h e n o t y p i c a n d P a t h o l o g i c D i f f e r e n c e s B e t w e e n BRCA1 a n d BRCA2 H e r e d i t a r y B r e a s t C a n c e r s By Kelly-Anne Phillips Abstract: Morphologically and clinically, breast cancer is a heterogeneous group of diseases. This heterogeneity may be a manifestation of differences in the molecular genetic events underlying distinct breast cancer pathogenesis pathways. Examination of hereditary breast cancers (HBC), which have in common an underlying germline mutation in BRCA1 or BRCA2, may provide further insight into this concept. Multiple studies have confirmed that BRCA1-associated HBC (BRCA1-HBC) generally exhibit a specific phenotype that is characterized by high tumor grade and estrogen receptor negativity. Conversely, discrepancies exist between the findings of studies that have examined BRCA2-HBC, and a specific phenotype has not been consistently described. The characteristic phenotype of BRCA1-associated tumors may prove a useful additional tool in selecting individuals with breast cancer who should be offered BRCA1 mutation testing, although further studies are required. Lastly, evidence is emerging to suggest that BRCA1 might be involved in the pathogenesis of a subgroup of non-HBC (by gene underexpression rather than mutation) and that these tumors may exhibit the same phenotype as their hereditary counterparts. J Clin Oncol 18:107s-112s
sj-xlsx-5-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-5-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-3-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-3-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-docx-6-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-docx-6-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-1-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-1-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-2-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-2-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
sj-xlsx-4-opp-10.1177_10781552231180875 - Supplemental material for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis
No full textSupplemental material, sj-xlsx-4-opp-10.1177_10781552231180875 for Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis by Marliese Alexander, Kim Jachno, Kelly-Anne Phillips and
John F Seymour, Monica A Slavin, Ada Cheung, Vivian Shen, Dana Maarouf, Rory Wolfe, Senthil Lingaratnam in Journal of Oncology Pharmacy Practice</p
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
- …
